Mice homozygous for the transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express Enhanced Green Fluorescent Protein (EGFP) and a truncated dominant-negative mouse transforming growth factor, beta receptor II (Tgfbr2) under the control of a bidirectional tetracycline transactivator responsive promoter (TRE; tetO). No fluorescence is observed in the tissues of this mutant. Primary cultures derived from ear biopsies exhibit green fluorescence when transfected with a tetracycline transactivator (tTA; "Tet-off") vector. When these transgenic mice are bred with other transgenic mice expressing reverse tetracycline-controlled transactivator protein (rtTA) or tetracycline-controlled transactivator protein (tTA), tissue-specific EGFP and dominant-negative Tgfbr2 transgene expression can be regulated with the tetracycline analog, doxycycline. This mutant mouse strain may be useful in studies of TGF-beta signaling.

These PTR mice express a transgene containing EGFP and a truncated dominant-negative mouse transforming growth factor, beta receptor II (<i>Tgfbr2</i>) and when bred with mice expressing rtTA or tTA, tissue-specific EGFP and dominant-negative <i>Tgfbr2</i> transgene expression can be regulated with doxycycline.

Typically mice are recovered in 12-16 weeks. Contact Customer Service to place an order or for more information.

<a target="_blank" href="https://www.jax.org/jax-mice-and-services/customer-support" rel="noreferrer">Contact Customer Service</a> for more information.